Use of salivary proteomics to monitor disease activity in periodontitis by Stewart, Kevin
• 9 participants were recruited from individuals 
seeking periodontal therapy. Selection criteria 
included severe periodontitis, good general health, 
non-smoker and no antibiotics in the past 3 months. 
• A saliva sample was collected from each individual 
prior to beginning periodontal therapy (saliva was 
stimulated by chewing on a bolus). A 2nd sample 
was collected at the completion of the periodontal 
treatment programme, typically 3-4 months later, 
when participants met clinical criteria for disease 
remission. 
• Saliva samples were separated using 2D SDS PAGE 
gel electrophoresis and individual spot intensities 
quantified using PDQuest software. 
• Paired t-tests were performed on log-normalised 
spot intensities from duplicate samples obtained 
before and after treatment. Spots which showed a 
significant difference (p<0.05, >1.5 fold change in 
abundance) were picked from the gels and analysed 
by mass spectroscopy using MALDI-TOF and LC-MS/
MS instruments. 
•  126 protein spots were compared across all saliva samples and 11 were found to be more abundant in the 
samples taken from individuals with severe periodontal disease when compared to their respective post-
treatment sample (P<0.05), while 4 protein spots were decreased (Figs 1 and 2).  
•  The predominant alteration observed was an increase in the abundance of the S100 proteins S100A8/A9 
(calprotectin) and S100A6. The S100A8/A9 heterodimer is expressed by neutrophils, activated macrophages and 
squamous epithelia. The increased levels observed in whole saliva likely result from active secretion by 
infiltrating neutrophils and inflamed keratinocytes, both of which secrete S100A8/A9 in the presence of 
bacterial lipopolysaccharides.  
•  Two acute phase response proteins were also identified, haptoglobin and transthyretin, which were increased 
and decreased in disease respectively. Of the remaining proteins with altered abundance, prolactin inducible 
protein and parotid secretory protein have previously been associated with host defence, while the function of 
the ubiquitous intracellular proteins transketolase, transaldolase and GDP-dissociation inhibitor B is less clear, 
but may reflect cellular damage in the inflamed gingiva.  
•  The high variation in basal levels of these proteins between individuals (Fig 3) suggests these protein changes 
would not be suitable for a screening tool to identify affected individuals, but may be useful in monitoring 
changes in the inflammatory response within an individual during periodontal treatment (Fig 2).  
• Periodontitis is a common disease characterised by the 
bacteria-induced inflammatory destruction of the 
support tissues of the teeth. Symptoms range from mild 
gum bleeding to severe inflammation and chronic 
destruction of tissue, ultimately requiring surgery and 
removal of teeth. 
• Periodontitis is episodic in nature; periods of 
inflammation and tissue destruction can alternate with 
periods of minor activity. 
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Fig 1  Protein spots with altered abundance in saliva during periodontal disease 
Spot #  Protein  Fold change 
in disease 
7621  Transketolase  5.4 
5334  Haptoglobin  3.6 
4426  unidentified  2.6 
6217  S100A8  2.5 
6116  S100A8  2.3 
6439  unidentified  2.3 
5526  Rab GDP dissociation inhibitor beta  2.2 
4321  S100A9  2.0 
3154  S100A6  1.6 
4517  Transaldolase 1  1.6 
4320  S100A9  1.5 
2317  Prolactin inducible protein  0.7 
3438  Parotid secretory protein  0.7 
4323  Transthyretin  0.7 
3432  unidentified  0.6 
Fig 2  Fold change of protein levels in each individual  
• Alterations in the salivary proteome were detected in samples from individuals with severe periodontal disease, 
suggesting local inflammation of gingival tissue may influence host defence activity throughout the oral cavity. 
•  The predominant alteration was an increase in the abundance of the S100 proteins S100A8/A9 (calprotectin) and 
S100A6, while changes in the levels of acute phase and other host defence proteins were also observed. 
•  These proteins may provide useful markers for monitoring disease activity during periodontal treatment. 
Fig 3  Groupwise comparison of protein levels 
Periodontal disease and saliva 
• Saliva is an important component of the host defence 
system of the oral cavity. It contains a variety of 
antimicrobial and immunomodulatory components. 
• Changes in salivary composition may reflect the 
presence of disease, as well as modulate the host 
defence activity of the oral cavity.  
• By investigating the effect of periodontal disease on 
saliva composition, we may identify new biomarkers for 
periodontal disease and learn how localised 
inflammation may influence host defence activity 
throughout the oral cavity. 
Objective of study 
To identify changes in the salivary proteome associated 
with periodontal disease activity 
This project was funded by the Waikato Institute of Technology, AgResearch Ruakura, the Waikato Medical Research Foundation and the New Zealand Dental Research Foundation 
400 ug of total saliva was focused on a pI 3-10 IPG strip and separated on a 13 % SDS-PAGE gel. Yellow circles indicate protein spots quantified. Red and blue circles identify 
spots significantly increased or decreased respectively in the disease versus post treatment samples (paired t-test, P<0.05). The table indicates protein identification and 
average fold change in disease versus post treatment sample. 
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Spot abundance normalised to combined average of disease and post treatment samples 
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